Product Description
Epirubicin is used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. Epirubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a603003.html)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, France
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Bladder Cancer|Hepatocellular Carcinoma|Inflammatory Breast Cancer|Muscle Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2019-005019-18 |
2019-005019-18 | P2 |
Active, not recruiting |
Breast Cancer |
2025-07-31 |
|||
NCT03515798 |
PELICAN | P2 |
Active, not recruiting |
Inflammatory Breast Cancer |
2022-08-22 |
2% |
2024-07-27 |
|
CTR20181618 |
CTR20181618 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20170169 |
CTR20170169 | P2 |
Active, not recruiting |
Muscle Cancer|Bladder Cancer |
None |
2025-04-29 |
||
CTR20231914 |
CTR20231914 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT06144944 |
PILHLE-002 | P3 |
Recruiting |
Breast Cancer |
2026-06-30 |
30% |
2024-11-27 |
Primary Endpoints|Treatments |
2011-001462-17 |
ADAPT | P3 |
Completed |
Breast Cancer |
2024-12-16 |
2025-05-06 |
Primary Completion Date|Study Completion Date |